(lp0
S'Analyst Activity  FBR &amp; Co Reiterates Buy on Alnylam Pharmaceuticals (NASDAQ ... Market Exclusive - 5 hours ago About Alnylam Pharmaceuticals  Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid  interference  therapeutics.Alnylam Pharmaceuticals Inc.  Moves Higher on Volume Spike for March 20 - Equities.comPromising Stocks in Spotlight: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ... - Rives Journal'
p1
aS"Here's Why Alnylam Pharmaceuticals, Inc. Stock Bounced Up 10.1% Today Motley Fool - Feb 27, 2017 Shares of Alnylam Pharmaceuticals, Inc.  a clinical-stage biotech, notched a 10.1% gain to end Monday's session.How Do Analysts View Alnylam Pharmaceuticals in 2017? - Market Realist"
p2
aS'The Medicines Company and Alnylam Pharmaceuticals Report Positive Final ... Yahoo Finance - Mar 17, 2017 The Medicines Company  and Alnylam Pharmaceuticals, Inc.  today announced positive final results from the ORION-1 Phase II study of inclisiran, an investigational, first-in-class PCSK9 synthesis inhibitor being developed for the treatment ...Alnylam touts latest trial data as suggesting its drugs are safe - Boston Business Journal'
p3
aS"Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc. Motley Fool - Feb 20, 2017 Late last year, Alnylam Pharmaceuticals, Inc.  took a big hit when the company scuttled an important development program because of safety concerns.Investors Alert -Alnylam Pharmaceuticals, Inc.'s  - Hot Stocks PointAlnylam Pharmaceuticals, Inc.  Updated Broker Ratings - NewsDen"
p4
aS'Alnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It Motley Fool - Feb 9, 2017 The Medicines Company  presented more positive data for their cholesterol-lowering drug inclisiran, which was called ALN-PCSsc before Alnylam out-licensed the drug. The Medicines Company is running a new phase 2 trial in patients with&nbsp;...Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial ... - Business Wire Alnylam  Q3 Loss Narrower than Expected, Revenues Rise - Nasdaq'
p5
aS'Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc. Motley Fool - Feb 6, 2017 Agenus  and Alnylam Pharmaceuticals  are both clinical-stage biotechs developing drugs that hold the potential to make a big difference for patients.'
p6
aS"What's Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure? Motley Fool - Oct 7, 2016 Alnylam Pharmaceuticals  announced on Oct. 5 that it was discontinuing development of revusiran in treating hereditary ATTR amyloidosis with cardiomyopathy .Alnylam Plunges 42% After Ending Development of a Key Medicine - BloombergAlnylam shares lose half their value as drug trial is halted - The Boston Globe"
p7
aS"Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data Motley Fool - Nov 4, 2016 Alnylam Pharmaceuticals  fell 12.6% on Thursday after reporting earnings Wednesday afternoon, but it's recovered some of that today."
p8
aS"Drilling Down Into the Charts for Alnylam Pharmaceuticals, Inc.  The USA Commerce - 12 hours ago We have gathered the technical data on Alnylam Pharmaceuticals, Inc. , and see some interesting trends in the stock's behavior of late."
p9
aS'Alnylam Pharmaceuticals Inc.  Moves Higher on Volume Spike for March 17 Equities.com - Mar 17, 2017 Alnylam Pharmaceuticals Inc.  traded on unusually high volume on Mar. 17, as the stock gained 1.41% to close at $55.25.Alnylam Pharmaceuticals, Inc.  Upgraded by Vetr Inc. to Strong-Buy - Chaffey BreezeIs It Time to go for Alnylam Pharmaceuticals, Inc. , Envision Healthcare ... - StockNewsJournal'
p10
a.